Sankyo, Santen Pharmaceutical to Collaborate in Developing Dry Eye Treatment.Tokyo, Japan, Oct 4, 2005 - (JCNN JCNN Japan Corporate News Network ) - Sankyo and Santen Pharmaceutical have signed a licensing agreement on CS-011 (rivoglitazone), Sankyo's proprietary agent designed for the treatment of diabetes. Under the agreement terms, the two companies will strive to develop a solution that uses CS-011 to act directly on corneal corneal pertaining to the cornea. See also keratitis, keratopathy. corneal anomaly includes microcornea, coloboma, megalocornea, dermoid, congenital opacity. corneal black body see corneal sequestrum (below). epithelial cells Epithelial cells Cells that form a thin surface coating on the outside of a body structure. Mentioned in: Corneal Transplantation and improve dry eye symptoms. Specifically, Sankyo will manufacture and supply CS-011 to Santen while Santen will be in charge of development, production and sales of the new solution. In addition, the two companies will collaborate in sales in Japan. Source: JCN JCN Japan Corporate News JCN Journal of Cognitive Neuroscience JCN Journal of Cardiovascular Nursing JCN Journal of Christian Nursing JCN Job Control Number JCN Journal of Child Neurology JCN joint communications network (US DoD) http://www.japancorp.net Copyright [c] 2005 Japan Corporate News Network. All rights reserved. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion